143 related articles for article (PubMed ID: 34193755)
1. A multicenter, phase II study of R-THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, indolent B-cell lymphoma.
Ohnishi K; Ohmachi K; Ando K; Yamamoto K; Ito T; Tanimoto M; Ohbayashi K; Ohyashiki K; Tsukasaki K; Naito K; Suzuki T; Ono T; Miyamura K; Kagami Y; Kinoshita T; Hotta T; Ogura M
J Clin Exp Hematop; 2021 Sep; 61(3):162-167. PubMed ID: 34193755
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of rituximab combined with pirarubicin-cyclophosphamide, vincristine and prednisolone regimen as first-line therapy for patients with indolent B-cell lymphoma.
Tsurumi H; Hara T; Goto N; Kitagawa J; Kanemura N; Yoshikawa T; Kasahara S; Goto H; Fukuno K; Yamada T; Sawada M; Shimizu M; Takahashi T; Takami T; Moriwaki H
Leuk Lymphoma; 2012 Feb; 53(2):247-53. PubMed ID: 21827339
[TBL] [Abstract][Full Text] [Related]
3. A multicenter, phase II study of full-dose THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, aggressive non-Hodgkin lymphoma.
Ohmachi K; Ogura M; Kagami Y; Imai Y; Hirose T; Kinoshita T; Nagai H; Ohnishi K; Hotta T
J Clin Exp Hematop; 2022; 62(4):202-207. PubMed ID: 36575000
[TBL] [Abstract][Full Text] [Related]
4. R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trial.
Hara T; Yoshikawa T; Goto H; Sawada M; Yamada T; Fukuno K; Kasahara S; Shibata Y; Matsumoto T; Mabuchi R; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Nannya Y; Katsumura N; Takahashi T; Kito Y; Takami T; Miyazaki T; Takeuchi T; Shimizu M; Tsurumi H
Hematol Oncol; 2018 Oct; 36(4):638-644. PubMed ID: 29882279
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma.
Mori M; Kitamura K; Masuda M; Hotta T; Miyazaki T; Miura AB; Mizoguchi H; Shibata A; Saito H; Matsuda T; Masaoka T; Harada M; Niho Y; Takaku F
Int J Hematol; 2005 Apr; 81(3):246-54. PubMed ID: 15814336
[TBL] [Abstract][Full Text] [Related]
6. 3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis.
Araie H; Sakamaki I; Matsuda Y; Tai K; Ikegaya S; Itoh K; Kishi S; Oiwa K; Okura M; Tasaki T; Hosono N; Ueda T; Yamauchi T
Intern Med; 2017 Sep; 56(18):2407-2413. PubMed ID: 28824057
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of the tetrahydropyranyl adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma.
Kasahara S; Hara T; Tsurumi H; Goto N; Kitagawa J; Kanemura N; Yoshikawa T; Goto H; Fukuno K; Yamada T; Sawada M; Takahashi T; Takami T; Moriwaki H
Leuk Lymphoma; 2011 Apr; 52(4):629-34. PubMed ID: 21438831
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma.
Ogura M; Morishima Y; Kagami Y; Watanabe T; Itoh K; Igarashi T; Hotta T; Kinoshita T; Ohashi Y; Mori S; Terauchi T; Tobinai K
Cancer Sci; 2006 Apr; 97(4):305-12. PubMed ID: 16630123
[TBL] [Abstract][Full Text] [Related]
9. Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.
Ogura M; Ishizawa K; Maruyama D; Uike N; Ando K; Izutsu K; Terui Y; Imaizumi Y; Tsukasaki K; Suzuki K; Izumi T; Usuki K; Kinoshita T; Taniwaki M; Uoshima N; Suzumiya J; Kurosawa M; Nagai H; Uchida T; Fukuhara N; Choi I; Ohmachi K; Yamamoto G; Tobinai K;
Int J Hematol; 2017 Apr; 105(4):470-477. PubMed ID: 27900638
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma.
Hara T; Tsurumi H; Goto N; Kitagawa J; Kanemura N; Yoshikawa T; Kasahara S; Goto H; Fukuno K; Yamada T; Sawada M; Yasuda I; Katsumura N; Takahashi T; Takami T; Moriwaki H
J Cancer Res Clin Oncol; 2010 Jan; 136(1):65-70. PubMed ID: 19590893
[TBL] [Abstract][Full Text] [Related]
11. [The efficacy and adverse effects of rituximab with CHOP or THP-COP in old-old and extremely old patients with diffuse large B cell lymphoma].
Kikukawa M; Miyazaki K; Kiuchi A; Abe S; Fujii H; Kanaya K; Shin K; Iwamoto T
Nihon Ronen Igakkai Zasshi; 2006 Mar; 43(2):236-40. PubMed ID: 16683659
[TBL] [Abstract][Full Text] [Related]
12. Pirarubicin, a novel derivative of doxorubicin. THP-COP therapy for non-Hodgkin's lymphoma in the elderly.
Kitamura K; Takaku F
Am J Clin Oncol; 1990; 13 Suppl 1():S15-9. PubMed ID: 2291455
[TBL] [Abstract][Full Text] [Related]
13. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
[TBL] [Abstract][Full Text] [Related]
14. Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study.
Tsurumi H; Yamada T; Sawada M; Kasahara S; Kanemura N; Kojima Y; Fukuno K; Hara T; Saio M; Takahashi T; Oyama M; Ozawa K; Takami T; Moriwaki H
J Cancer Res Clin Oncol; 2004 Feb; 130(2):107-13. PubMed ID: 14648210
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
Itoh K; Ohtsu T; Fukuda H; Sasaki Y; Ogura M; Morishima Y; Chou T; Aikawa K; Uike N; Mizorogi F; Ohno T; Ikeda S; Sai T; Taniwaki M; Kawano F; Niimi M; Hotta T; Shimoyama M; Tobinai K;
Ann Oncol; 2002 Sep; 13(9):1347-55. PubMed ID: 12196359
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
Nishioka T; Tsuchiya K; Nishioka S; Kitahara T; Ohmori K; Homma A; Aoyma H; Shindoh M; Shirato H
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):847-52. PubMed ID: 15465202
[TBL] [Abstract][Full Text] [Related]
17. CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.
Shibata Y; Hara T; Kasahara S; Yamada T; Sawada M; Mabuchi R; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Kito Y; Goto N; Miyazaki T; Takami T; Takeuchi T; Shimizu M; Tsurumi H
Hematol Oncol; 2017 Jun; 35(2):163-171. PubMed ID: 26449182
[TBL] [Abstract][Full Text] [Related]
18. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy.
Iioka F; Izumi K; Kamoda Y; Akasaka T; Ohno H
Int J Clin Oncol; 2016 Jun; 21(3):498-505. PubMed ID: 26463529
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.
Oh SY; Kim WS; Kim JS; Kim SJ; Yoon DH; Yang DH; Lee WS; Kim HJ; Yhim HY; Jeong SH; Won JH; Lee S; Kong JH; Lim SN; Ji JH; Kwon KA; Lee GW; Lee JH; Lee HS; Shin HJ; Suh C
Cancer Commun (Lond); 2019 Oct; 39(1):58. PubMed ID: 31619290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
